作者: Huihui Ye , Adam G. Sowalsky
DOI: 10.1016/J.UROLONC.2017.12.022
关键词:
摘要: Clinicopathologic parameters, including Gleason score, remain the most validated prognostic factors for patients diagnosed with localized prostate cancer (PCa). However, of same risk groups have exhibited heterogeneity disease outcomes. To improve classification, multiple molecular classifiers been developed, which were designed to inform beyond existing clinicopathologic classifiers. Alterations affecting tumor suppressors and oncogenes, such as PTEN, MYC, BRCA2, TP53, long associated aggressive PCa, demonstrated grade-dependent frequency alterations in PCas. In addition these genetic hallmarks, several RNA-based commercial tests recently developed help identify men who would benefit from earlier interventions. Large genomic studies also correlate germline epigenetic features adverse outcomes, further strengthening link between metastasis a stepwise accumulation driver lesions.